Related Experiment Video
Updated: Aug 11, 2026
Cutaneous Leishmaniasis in the Dorsal Skin of Hamsters: a Useful Model for the Screening of Antileishmanial Drugs
Published on: April 21, 2012
Effect of liniment levamisole on cellular immune functions of patients with chronic hepatitis B
Ke-Xia Wang1, Li-Hua Zhang, Jiang-Long Peng
1Department of Pathogenic Biology, School of Medicine, Anhui University of Science and Technology, Huainan 232001, Anhui Province, China. cpli@aust.edu.cn
Insights
Liniment levamisole treatment enhanced cellular immunity in chronic hepatitis B patients by increasing T lymphocyte subsets (CD3+, CD4+) and the CD4+/CD8+ ratio. This suggests a potential therapeutic benefit for immune function.
Area of Science:
- Immunology
- Hepatology
- Pharmacology
Background:
- Chronic hepatitis B (CHB) is a significant global health concern.
- Cellular immune dysfunction is a hallmark of CHB pathogenesis.
- Exploring immunomodulatory agents is crucial for CHB management.
Purpose of the Study:
- To investigate the impact of liniment levamisole on cellular immune functions in patients with CHB.
- To assess changes in T lymphocyte subsets and interleukin-2 receptor expression.
Main Methods:
- Biotin-streptavidin (BSA) technique was employed to quantify T lymphocyte subsets (CD3+, CD4+, CD8+) and membrane-bound interleukin-2 receptor (mIL-2R).
- Measurements were performed on peripheral blood mononuclear cells (PBMCs) from CHB patients before and after a course of liniment levamisole treatment.
Main Results:
- Treatment with liniment levamisole led to a significant increase in CD3+ and CD4+ T lymphocyte levels.
- The ratio of CD4+/CD8+ T cells increased, while CD8+ T cell levels decreased post-treatment.
- Total expression of mIL-2R in PBMCs showed an increase following liniment levamisole administration.
Conclusions:
- Liniment levamisole demonstrates potential to reinforce cellular immune functions in patients suffering from chronic hepatitis B.
- The observed immunomodulatory effects warrant further investigation into levamisole's therapeutic role in CHB.
Aim:
To explore the effects of liniment levamisole on cellular immune functions of patients with chronic hepatitis B.
Methods:
The levels of T lymphocyte subsets and mIL-2R in peripheral blood mononuclear cells (PBMCs) were measured by biotin-streptavidin (BSA) technique in patients with chronic hepatitis B before and after the treatment with liniment levamisole.
Results:
After one course of treatment with liniment levamisole, the levels of CD3(+), CD4(+), and the ratio of CD4(+)/CD8(+) increased as compared to those before the treatment but the level of CD8(+) decreased. The total expression level of mIL-2R in PBMCs increased before and after the treatment with liniment levamisole.
Conclusion:
Liniment levamisole may reinforce cellular immune functions of patients with chronic hepatitis B.
